MicroIslet Inc. Addresses Global Diabetes Summit
Published: Aug 13, 2008
SAN DIEGO--(BUSINESS WIRE)--MicroIslet Inc. (OTCBB: MIIS, http://www.microislet.com), a biotechnology company engaged in the development and commercialization of cell therapies for diabetes, is pleased to report on the Company’s presentation at the XXII International Congress Of The Transplantation Society Meeting, being held August 10-14, 2008, at the Sydney Convention & Exhibition Centre in Sydney, Australia. Drs. Ingrid Stuiver and Amaresh Basu, MicroIslet’s Senior Director and Vice President of R&D, respectively, discussed the Company’s developmental advances at the global transplantation meeting.